Concepedia

Toshiyuki Tsukaguchi

TT

Statistics

Publications

15

Citations

1.6K

H-Index

14

Active since

1993

Affiliations

Chugai Pharma (United States)(Current)

Roche (Switzerland)

Toshiyuki Tsukaguchi is an author at Chugai Pharma (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

1993–2018

15

Publications

15

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell · 2011 · 625 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

Tatsushi Kodama, Toshiyuki Tsukaguchi, Miyuki Yoshida et al. · Cancer Letters · 2014 · 197 citations

Medicine, Oncology, Pharmacology +10

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi et al. · Bioorganic & Medicinal Chemistry · 2011 · 164 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +8

Alectinib Shows Potent Antitumor Activity against <i>RET</i> -Rearranged Non–Small Cell Lung Cancer

Tatsushi Kodama, Toshiyuki Tsukaguchi, Yasuko Satoh et al. · Molecular Cancer Therapeutics · 2014 · 156 citations · Full text

Medicine, Oncology, Pharmacology +17

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2014 · 120 citations · Full text

Medicine, Oncology, Pharmacology +15

1–5 of 15